Latest news with #lifeSciences
Yahoo
10 hours ago
- Business
- Yahoo
Life sciences struggles with oversupply in Q1, but upsides exist, experts say
This story was originally published on Facilities Dive. To receive daily news and insights, subscribe to our free daily Facilities Dive newsletter. After growing steadily throughout 2024, the U.S. life sciences real estate sector is experiencing turbulence in 2025 due to business uncertainty, which resulted in a sharp drop-off in demand for lab space during the first quarter, according to a report by JLL. Oversupply increased slightly year over year, with the more than 200 million square feet of U.S. lab market space needing 20 million to 25 million square feet of net absorption or supply reduction to return to market equilibrium, JLL says in its 2025 life sciences property report. 'Barring an unforeseen and substantial growth spurt of demand, the likeliest outcome of this period of oversupply is that well-built and well-located buildings will gain market share,' JLL says in the report, noting that landlords with scale and experience in the space are out-leasing their competition. 'Buildings without those aspects will face increased odds of distress in the next 12-24 months.' Although there are high-potential labs in need of updated operations and working capital to provide opportunities, the firm anticipates a supply shake-up, with many building owners unable to wait indefinitely for markets to recover, per the report. Today, smaller deals are driving market activity, making up 76% of deals closed in the first quarter, JLL said. The firm noted that reductions in tenant demand across the U.S. — influenced by macroeconomics, policy and funding uncertainties — suggest 'muted leasing volume growth' through 2025 as the sector grapples with 'a rocky decision-making environment.' JLL says sustained elevated supply has led to significant downward pressure on rents in key markets, namely Boston, the Bay Area and San Diego. Midsize markets —such as the greater Washington, D.C., area; New Jersey; and Raleigh-Durham, North Carolina — occupy a more stable middle ground, showing 'decent availability levels and moderate rent changes,' JLL says in its report. There is relative resilience in the U.S. life sciences workforce, coupled with right-sizing and life sciences tenants using their space more efficiently, according to Ian Anderson, senior director of research for life sciences at CBRE. 'It's actually helping stem some of the negative effects of oversupply of life sciences real estate we've seen over the last few years,' Anderson said on a CBRE webinar. 'Though we have a while to go to address some of the oversupply in the life sciences real estate space, we are headed in the right direction … with tenants becoming more efficient with space,' Anderson said. JLL echoed this sentiment, noting that owners of struggling buildings experiencing elevated vacancy levels have started to change uses, leading to a reduction in built lab space that could help to alleviate oversupply. The firm says that it is tracking 3.2 million square feet in the process of changing uses, with half of this due to a pivot toward or lease to a new user type, with the other half due to capital challenges. One such potential user type is AI-focused tech firms, which are experiencing significant growth and are in need of space, according to CBRE. While the flight to quality has already begun to force office occupiers to consider less-than-prime buildings, the life sciences sector still has a large supply of high-end buildings available in top markets like San Francisco, according to Mary Hines, vice chair of life sciences in the San Francisco Bay Area at CBRE. 'What we saw during the pandemic was that developers spent a lot of money building out Class A life science buildings, a number of those are still available and in shell condition,' Hines said. 'The ones located in the right locations are going to need to catch the eye of these fast-growing AI companies that need space.' In addition, both life sciences and AI companies share a growing need for reliable power. 'Given the long lead times in the Bay Area for power, and how difficult it is to get if your building doesn't have it, that is creating a lot of demand for buildings that have power in place,' Hines said. 'So I do predict that we're going to likely see a lot of these Class A life science projects get leased by AI companies.' In addition, there are opportunities for tenants to relocate manufacturing functions — those that are normally pushed to tertiary or secondary markets due to the high cost of building — to be closer to headquarters, which are usually situated in the core markets. We've seen the softening of rents, and landlords have been more competitive in actually giving more tenant improvement dollars,' Hines said. 'So that creates the potential for these companies to locate their manufacturing nearby.' Recommended Reading AI set to spur changes in life sciences facility needs Sign in to access your portfolio
Malay Mail
11 hours ago
- Business
- Malay Mail
DHL commits to helping Indonesia expand its fast-growing sectors and aid its rise as a global trade hub
Offers comprehensive end-to-end solutions tailored for Indonesian businesses' unique needs and multinational enterprises seeking to expand locally Sees opportunities in the new energy, life sciences and healthcare, and e-commerce sectors Supports Indonesia's net-zero ambitions and businesses on their decarbonization journeys through a series of targeted initiatives From left to right: Ahmad Mohamad (Senior Technical Advisor, DHL Express Indonesia), Nicholas Bongsosartono (President Director, DHL Global Forwarding Indonesia), Matthias Gehrsitz (Managing Director, DHL Supply Chain Indonesia) Multimodal transportation management Specialized warehousing with critical value-added services such as battery testing and charging Comprehensive aftermarket battery handling solutions Dedicated team of EV logistics specialists who possess deep knowledge in navigating the sector's complex logistical demands while maintaining the highest standards of safety and compliance. DHL Global Forwarding Life Science and Healthcare (LSH) Competency Centre in Jakarta offers specialized storage facilities that maintain temperatures of 2–8°C and 15–25°C, ensuring product integrity and regulatory adherence with the support of trained experts. DHL Medical Express is a premium service that combines the division's logistics expertise with a dedicated and unique range of features to create a flexible solution for the Life Sciences industry. Secure, temperature-controlled transport of vital medical goods through specialized packaging maintains the integrity of vital pharmaceuticals and biotechnological materials. DHL Supply Chain offers deep expertise for various needs, ranging from pharmaceuticals and medical devices to logistics for clinical trials and supply chain consultancy and inventory management for hospital and health services. DHL Express Indonesia is leading the way to reduce the industry's carbon footprint with its GoGreen Plus service, which enables customers to reduce their greenhouse gas emissions by up to 80% through the use of Sustainable Aviation Fuel (SAF). DHL Express currently also deploys 28 electric vehicles for first and last-mile deliveries, as part of its progress in reaching the DHL Group 's global target to electrify over 66% of its pick-up and delivery fleet by 2030. DHL Global Forwarding Indonesia is among the industry's first to pilot electric van for inner-city deliveries, while offering sustainable marine and aviation fuels through its GoGreen Plus solutions to enable customers to easily reduce their main haul carbon emissions across all trade lanes. DHL Supply Chain Indonesia delivers sustainable logistics solutions – from carbon-neutral warehouses powered by solar PV (covering 30% of energy needs), to five regulatory-compliant EV units. Additional eco-friendly measures at the sites, such as rainwater harvesting systems and the adoption of reusable pallets and packaging, ensure that environmental impact is minimized across every supply chain touchpoint. The division also has a dedicated team of EV logistics experts who are ready to support the growth of Indonesia's commercial EV sector through reliable and compliant supply chain solutions. JAKARTA, INDONESIA- Media OutReach Newswire - 20 June 2025 - DHL, the world's leading logistics company, through its Strategy 2030 – Accelerate Sustainable Growth, is focused on supporting Indonesia's ambitions as a key player in both regional and global trade. According to the DHL Trade Atlas 2025 , Indonesia is expected to rank in the top 30 countries for trade growth in speed and scale over the next five years. Its dynamic economy, driven by rapid digital transformation and strategic infrastructure investments, presents significant opportunities for businesses. However, a volatile business environment – characterized by geopolitical tensions and shifting trade patterns – poses challenges and uncertainties for the presence of three DHL Group divisions – DHL Express, DHL Global Forwarding, and DHL Supply Chain – businesses based in Indonesia can tap into end-to-end logistics offerings across the divisions, access a vast global logistics network, and lean on deep expertise to help navigate fluctuating trade complexities. Additionally, the DHL divisions are especially focused on supporting the expansion of fast-growing sectors in Indonesia such as electric vehicles (EVs), life sciences and healthcare, as well as e-commerce and retail."Indonesia's neighbors have been getting all the attention recently when it comes to supply chain resiliency, but this country has much to offer. We have a large domestic market and talent pool, and the government has been investing in modernizing its logistics sector through the National Logistics Ecosystem also see growth opportunities in cities beyond the Greater Jakarta area, such as Surabaya, Semarang, Batam, and Bali, among others, which are viable alternatives for businesses looking to diversify their supply chains. More importantly, we also want to help Indonesian brands expand their horizon beyond the local market through e-commerce," said Ahmad Mohamad, Senior Technical Advisor of DHL Express addition to international brands expanding into Indonesia, there is also a growing pool of Indonesian brands that are going global. Indonesia's strategic location and proximity to major markets in the region make it an attractive location as a global trade hub. It is actively part of at least 12 major bilateral and multi-lateral trade agreements, including the Regional Comprehensive Economic Partnership (RCEP), currently the world's largest free trade Group has been investing in Indonesia to help boost the country's logistics and supply chain capabilities. It has more than 4,000 employees in the country, with approximately 180 facilities across Indonesia, to help cater to the needs of rapidly growing companies in the country."Another sector that we see massive growth opportunities in is new energy in Indonesia, particularly EV batteries. Indonesia's goal of becoming one of the world's top three EV battery producers by 2027 is also in line with our Strategy 2030 focus in this last year, we have seen at least seven EV manufacturers commit to building production facilities in the country. There is also keen interest from many China EV enterprises looking for a logistics partner that can deliver safe and compliant end-to-end logistics. Our existing experience in the automotive industry with customers such as Chery and Wuling Motors, along with regional capabilities and know-how in the EV industry, puts us in a prime position to help EV players navigate the Indonesian landscape," said Matthias Gehrsitz, Managing Director, DHL Supply Chain support this fast-growing industry, DHL's customers in this sector have access to a comprehensive end-to-end logistics solution tailored specifically for EV supply chains. This includes:"Indonesia's life science and healthcare (LSHC) sector is large, but still developing. As a country, we've always been heavily reliant on imports in this sector, but there is a push by the government to reduce imports and be more self-reliant. It is projected that the pharmaceutical sector market value will increase to US$11 billion (~EUR9.5 billion) in us, this would mean investing in the proper logistics infrastructure to support this ambition, such as implementing specialized cold-chain solutions that encourage companies to establish their facilities here in Indonesia," said Nicholas Bongsosartono, President Director, DHL Global Forwarding has been investing in Indonesia ahead of the curve to meet market demands:DHL Group has also recently announced a strategic investment of €500 million to bolster its Life Sciences and Healthcare (LSHC) infrastructure across all business units in Asia Pacific . With its new sector brand, DHL Health Logistics, the Group consolidates its life sciences and healthcare expertise under one unified umbrella, creating a seamless, end-to-end experience for customers that simplifies the management of complex, cross-border supply ambitions to be a frontrunner in low-carbon logistics operations are also aligned with Indonesia's sustainability ambitions. The country wants to reduce greenhouse gas emissions by 29% by 2030 and achieve a low-carbon economy by 2060 or sooner. It also aims to phase out fossil-fuel power plants by 2039 and significantly expand renewable energy capacity. DHL is supporting Indonesia's sustainability targets in several ways:Hashtag: #DHL The issuer is solely responsible for the content of this announcement. DHL – The logistics company for the world DHL is the leading global brand in the logistics industry. Our DHL divisions offer an unrivalled portfolio of logistics services ranging from national and international parcel delivery, e-commerce shipping and fulfillment solutions, international express, road, air and ocean transport to industrial supply chain management. With approximately 400,000 employees in more than 220 countries and territories worldwide, DHL connects people and businesses securely and reliably, enabling global sustainable trade flows. With specialized solutions for growth markets and industries including technology, life sciences and healthcare, engineering, manufacturing & energy, auto-mobility and retail, DHL is decisively positioned as "The logistics company for the world". DHL is part of DHL Group. The Group generated revenues of approximately 84.2 billion euros in 2024. With sustainable business practices and a commitment to society and the environment, the Group makes a positive contribution to the world. DHL Group aims to achieve net-zero emissions logistics by 2050.
Yahoo
a day ago
- Business
- Yahoo
Labviva Showcases Advanced AI Procurement Tools at the R&D Procurement and Sourcing in Pharma Summit 2025
Global leader in source-to-pay solutions for life sciences to showcase an array of automated procurement technologies Labviva at R&D Procurement & Sourcing in Pharma Summit BOSTON, June 19, 2025 (GLOBE NEWSWIRE) -- Labviva, the leading AI procurement platform for life sciences, today announced its plans to demonstrate how pharmaceutical and biotech companies can leverage AI for laboratory procurement to drive cost and resource efficiencies and accelerate the pace of scientific innovation. The company will showcase its purchasing platform and inventory management solution (IMS) and plans to debut a new AI solution at the R&D Procurement & Sourcing in Pharma Summit, located at the Hilton Boston Logan Airport on June 24-26. Co-presenting panel on 'Modernizing Inventory Management: How Neutral Models Are Enabling Smarter Lab Operations' This panel will focus on lessons learned, change leadership, and value delivered through a vendor-neutral approach to inventory management. It will also highlight: How Takeda modernized its lab supply strategy with a vendor-agnostic, data-driven approach to inventory management How a neutral model improved visibility, reduced waste, and gave Takeda more control over their supply needs How Boston Lab Services and Labviva partnered to deliver automation, flexibility, and operational excellence Actionable insights for transforming procurement from a cost center into a strategic R&D enabler The talk will take place at the R&D Procurement & Sourcing in Pharma Summit at 10:00 a.m. on June 26. It will be moderated by Kleida Martiro, Partner at Glasswing Ventures and panelists include Hillary Ferrer, R&D Operations at Takeda, Andrew Petterelli, Procurement at Takeda, Elden Lainez, CEO of Boston Lab Services and Nick Rioux, CTO of Labviva. Labviva's R&D Procurement Cocktail Reception Show attendees and members of the press can RSVP for Labviva's cocktail event which takes place at the Hilton Boston Logan Airport, One Hotel Dr, Boston, MA 02128, on June 24th from 5:00pm-6:00pm. 'At the R&D Procurement & Sourcing in Pharma Summit, we plan to demonstrate the value of modernizing research procurement processes using AI automation,' said Siamak Baharloo, CEO of Labviva. 'In an era of tariffs and trade wars, compliance and efficiency are king. And with Labviva, pharmaceutical procurement teams enjoy improved transparency, diverse supplier access, broad product and pricing options, and the inventory controls they need to ensure compliance, supply chain security, and mass efficiencies while maintaining complete control of their data.' To schedule a meeting or press interview with Labviva, please contact Jennifer Olszewski at jolszewski@ About LabvivaLabviva connects researchers with suppliers of reagents, chemicals, and instrumentation in an intuitive, user-friendly platform that supports the priorities of scientists while staying compliant with purchasing rules. Suppliers can easily manage the content of their products, and products are mapped into scientific applications, techniques and protocols. To learn more about how Labviva accelerates the science of life, visit us at Media Contacts:Jennifer OlszewskiLabviva917-445-4454jolszewski@ or Michael IngallsPenVine for Labviva917-494-4909michael@ A photo accompanying this announcement is available at in to access your portfolio
Yahoo
2 days ago
- Business
- Yahoo
Novo Holdings Reports Strong Momentum in Asia Across Healthcare and Planetary Health in 2024
Landmark investments, portfolio progress, and expanded presence positionNovo Holdings for long-term growth and impact in Asia SINGAPORE, June 18, 2025 /PRNewswire/ -- Novo Holdings today released its Asia Investments Year in Review 2024, highlighting a year of strategic growth and purpose-driven investing across healthcare, life sciences, and planetary health in key Asian markets. The report underscores Novo Holdings' commitment to building long-term partnerships that deliver both financial returns and societal impact. Now in its fifth year, the Novo Holdings Asia platform continues to strengthen its footprint across the region, with teams based in Singapore, Shanghai, and an upcoming office in Mumbai. Highlights from 2024 include: Largest-ever Asia investment in India's Manipal Hospitals, a leading provider of high-quality, affordable healthcare First Planetary Health investment in Asia, backing AgNext Technologies in India to enhance food quality and safety using AI Enhanced presence in China with the opening of an expanded office in Shanghai, reaffirming long-term regional commitment Continued support for digital health innovators, including follow-on investments in and MedGenome The Year in Review also reflects positive progress across Novo Holdings' Asia portfolio, with key portfolio milestones including FDA clearance for lung nodule detection tool, strategic acquisitions by Manipal Hospitals and Medi Assist, and the launch of Doctor Anywhere's integrated MedSuites facility in Singapore. Amit Kakar, Managing Partner and Head of Asia at Novo Holdings, said:"In 2024, we advanced our mission of investing in innovation that improves lives, through strengthening healthcare systems, advancing AI in diagnostics, and enabling more sustainable food production. These investments reflect the scale and urgency of the challenges Asia faces, and the opportunity to be part of transformative solutions. Looking ahead, we are excited to continue expanding our regional platform, deepening our partnerships, and identifying new ways to drive impact at the intersection of health, science, and sustainability." Read the full review at: About Novo HoldingsNovo Holdings is a holding and investment company responsible for managing the assets and wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people's health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (formerly Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure, and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health, and Principal Investments teams, Novo Holdings invests in life sciences companies at all stages of development. As of year-end 2024, Novo Holdings had total assets of EUR 142 Further information: Paul Ewing-ChowHead of Corporate Affairs Asiapec@ View original content: SOURCE Novo Holdings
Yahoo
3 days ago
- Business
- Yahoo
TraceLink Unveils OPUS Link Lab: A Radical Leap Forward for Multienterprise Supply Chain Innovation
BOSTON, June 17, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent supply chain orchestration, has launched OPUS Link Lab (OLL)—a revolutionary, no-cost design environment created to supercharge the creation and commercialization of multienterprise solutions across the life sciences ecosystem. Sparked by significant customer and partner demand, OPUS Link Lab empowers solution developers, IT leaders, and technologists with a free, secure, and always-on, no-code design environment packed with TraceLink's most advanced orchestration capabilities. Users can immediately begin designing, testing, and demoing transformative supply chain solutions leveraging: B2N (Business-to-Network) Integrate-Once™ - With OPUS's B2N Integrate-Once™ model, customers and trading partners integrate a single time and instantly link to any partner on the network. No more rebuilding the same integration for every relationship; just link in and scale through many OPUS solutions. Multienterprise Information Network Tower (MINT) - Provides end-to-end, real-time transaction visibility and intelligence across the life sciences and healthcare supply chain, enabling companies and their trading partners to make faster, data-driven decisions and proactively source real-time, end-to-end commercial and supply chain information for advancing GenAI strategies. Process Orchestration for Empowered Teams (POET) - Streamlines and automates cross-functional, person-to-person business processes, empowering teams with real-time collaboration, transparency, and control to drive faster, more accurate outcomes. OPUS Solution Environment (OSE) – A breakthrough no-code toolset enabling users to rapidly assemble enterprise and multienterprise solutions with drag-and-drop ease. OPUS Reports and Dashboards (ORD) – A robust, no-code reporting and analytics suite that allows business users to create real-time visualizations and performance dashboards of end-to-end supply chain information, enabling leaders to gain instant visibility into supply chain KPIs for faster decision-making and data-driven execution. Link Actions and Transforms - Rapidly build event-driven links between OPUS solutions and common enterprise systems using Link Actions and apply dynamic, no-code transforms to standardize and route data across systems. This combination enables fast, flexible integration with enterprise applications without the time and cost of custom development. "OPUS Link Lab accelerates digital transformation by giving innovators everything they need to create, test, and deploy supply chain solutions without barriers," said Shabbir Dahod, President and CEO of TraceLink. "With OLL and our no-code OPUS Solution Environment, anyone—from system integrators to in-house IT teams—can rapidly turn ideas into multienterprise-grade solutions that improve agility, resilience, and business performance with trading partners." With OPUS Link Lab, users can rapidly and affordably digitalize processes and craft tailored solutions to solve real-world, multienterprise supply chain challenges, including: Commercial and Channel Management. Order-to-cash/procure-to-pay optimization, channel inventory control and optimization, demand sensing, financial reconciliation and claims adjudication. Supply Chain Planning. Forecast and scenario planning, production planning and scheduling, material and resourcing planning, S&OP alignment. External Manufacturing and Manufacturing Execution. Forecast and order planning, production tracking, material supply coordination, tech transfer collaboration, resource planning, and OEE monitoring. Quality Management. Continuous quality improvement, batch record review collaboration, issue and exception resolution, compliant and adverse event management. Procurement and Supplier Management. Agreement and licensing coordination, qualification and performance assessment, sustainability scorecarding. Regulatory Affairs and Compliance. Regulatory submission and tracking, label and artwork management, risk and impact assessment, and inspection and audit management. OPUS Link Lab also includes access to curated training paths, hands-on documentation, pre-built solution templates, and community forums led by TraceLink experts—all designed to fast-track network ecosystem success. Whether you're building your first digital orchestration flow or scaling multienterprise solutions across global networks, OPUS Link Lab makes it possible—today. Learn more about OPUS Link Lab and register for access here. About TraceLinkTraceLink Inc. is the largest end-to-end intelligent supply chain platform for life sciences and healthcare, enabling end-to-end orchestration by connecting more than 291,000 healthcare and life sciences entities through its B2N Integrate-Once™ network. Leading businesses trust TraceLink to deliver complete global connectivity, visibility, and traceability of healthcare products, ensuring that every patient gets the medicines they need when needed, safely and securely. SOURCE Tracelink, Inc.
